INT142682

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 2.40
Pain Relevance 0.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (EMR1) plasma membrane (EMR1) signal transducer activity (EMR1)
EMR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 1 55.92 Quite High
positron emission tomography 2 45.12 Quite Low
imagery 4 41.76 Quite Low
alcohol 4 25.40 Quite Low
Inflammation 3 25.00 Low Low
Inflammatory response 1 25.00 Low Low
cytokine 24 5.00 Very Low Very Low Very Low
depression 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 32 95.92 Very High Very High Very High
Cancer 179 95.16 Very High Very High Very High
Colon Cancer 5 87.68 High High
Apoptosis 10 85.48 High High
Lung Cancer 1 83.28 Quite High
Papillomavirus Infection 22 71.60 Quite High
Skin Allergy 2 61.28 Quite High
Sprains And Strains 2 61.20 Quite High
Exanthema 7 57.76 Quite High
Diarrhoea 1 57.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Cetuximab is a human/mouse chimeric monoclonal antibody that binds to the EGF receptor, competitively inhibiting ligand binding, and inducing receptor dimerization and downregulation.
EGF receptor Binding (binds) of
1) Confidence 0.26 Published 2007 Journal Expert Opin Drug Saf Section Abstract Doc Link 17367263 Disease Relevance 0.87 Pain Relevance 0.06
A variety of EGFR inhibitors have been developed that function either by binding to the extracellular ligand binding domain of the EGF receptor (e.g., MAbs such as cetuximab), or by inhibiting the intracellular tyrosine kinase activity of the receptor [65, 66].
EGF receptor Binding (binding) of
2) Confidence 0.01 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2723756 Disease Relevance 0.68 Pain Relevance 0
The monoclonal antibody (MAb) cetuximab, which binds to the EGF receptor, is approved by the US Food and Drug Administration as first-line treatment of locally or regionally advanced HNSCC in combination with radiotherapy.
EGF receptor Binding (binds) of
3) Confidence 0.01 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2723756 Disease Relevance 0.85 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox